Development and Validation of a Computational Histology Artificial Intelligence–Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials

JCO Precision Oncology · Published 2026-07-01 · DOI 10.1200/po-26-00321

Free full text

Authors (28)

Christopher J. Sweeney, Vrishab Krishna, Viswesh Krishna, Akshay Neema, Asit Tarsode, Vinod V. Subhash, Lisa G. Horvath, James G. Kench, Martin R. Stockler, Sonia Yip, Hayley Thomas, Umang Swami, Haochen Zhang, Snehal Sonawane, Waleed M. Abuzeid, Vivek Nimgaonkar, Ekin Tiu, Drew Watson, Lesli Kiedrowski, Trevor J. Royce, David D. Yang, Phuoc T. Tran, Charles J. Ryan, Paul L. Nguyen, Alicia K. Morgans, Anirudh Joshi, Neeraj Agarwal, Ian D. Davis

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Sweeney, C., Krishna, V., Krishna, V., et al. (2026). Development and Validation of a Computational Histology Artificial Intelligence–Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials. JCO Precision Oncology. https://doi.org/10.1200/po-26-00321

Related articles

• Prediction of Anthracycline Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study · JCO Precision Oncology · 2026 · Same journal
• Integrated Radioproteomic Modeling for Early Recurrence Prediction and Metabolic Characterization in Hepatocellular Carcinoma · JCO Precision Oncology · 2026 · Same journal
• Hypoalbuminemia as a Predictive Biomarker of Dyspnea Response to Dexamethasone and Placebo in Patients With Cancer: Secondary Analysis of the ABCD Randomized Clinical Trial · JCO Precision Oncology · 2026 · Same journal
• Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study · JCO Precision Oncology · 2026 · Same journal
• Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I · JCO Precision Oncology · 2026 · Same journal
• DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers · JCO Precision Oncology · 2026 · Same journal
• Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis · JCO Precision Oncology · 2026 · Same journal
• Personalized Molecular Monitoring of a Cryptic DIAPH1::PDGFRB Fusion in Chronic Eosinophilic Leukemia Using Droplet Digital Polymerase Chain Reaction · JCO Precision Oncology · 2026 · Same journal
• Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma · JCO Precision Oncology · 2026 · Same journal
• Liquid Biopsy Monitoring in BRAF V600E–Mutated Patients With Non–Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020) · JCO Precision Oncology · 2026 · Same journal